Caryn Lerman
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (5)
Background: Cancer centers are expected to engage communities and reduce the burden of cancer in their catchment areas. However, the extent to which cancer centers adequately reach the entire US population is unknown. Methods: We surveyed all members of the Association of American Cancer Institutes ( N = 102 cancer centers) to document and map each cancer center's primary catchment area. Catchment area descriptions were aggregated to the county level. Catchment area coverage scores were calculated for each county and choropleths generated representing coverage across the US. Similar analyses were used to overlay US population density, cancer incidence, and cancer-related mortality compared with each county's cancer center catchment area coverage. Results: Roughly 85% of US counties were included in at least one cancer center's primary catchment area. However, 15% of US counties, or roughly 25 million Americans, do not reside in a catchment area. When catchment area coverage was integrated with population density, cancer incidence, and cancer-related mortality metrics, geographical trends in both over- and undercoverage were apparent. Conclusions: Geographic gaps in cancer center catchment area coverage exist and may be propagating cancer disparities. Efforts to ensure coverage to all Americans should be a priority of cancer center leadership. Impact: This is the first known geographic analysis and interpretation of the primary catchment areas of all US-based cancer centers and identifies key geographic gaps important to target for disparities reduction. See related commentary by Lieberman-Cribbin and Taioli, p. 949
Year:
2025
Background: Survivors of adolescent and young adult (AYA, ages 15–39 years at diagnosis) cancer are at increased risk for subsequent malignant neoplasms (SMN), of which lung cancer is the most lethal. Factors contributing to lung SMN development and outcomes are not well characterized. Methods: Survivors of AYA cancer diagnosed between 1998 and 2020 were identified in the California Cancer Registry ( n = 251,632). Pearson’s χ 2 and Fisher’s exact tests were used to determine associations between sociodemographic and cancer characteristics and SMN status. Multivariable Cox proportional hazard regression, adjusting for age, time from primary diagnosis, race/ethnicity, insurance, primary cancer site, stage, and treatment, evaluated associations between these characteristics and the incidence and mortality of lung cancer as first SMN. Results: A total of 675 (0.7%) survivors were diagnosed with lung SMN, of whom 487 (72.1%) died. The median time from primary diagnosis to lung SMN was 13.0 years (IQR 4.0–20.0 years). Nearly half (46.5%) of survivors with lung SMN had metastatic disease. Non-Hispanic Black survivors were more likely than non-Hispanic White survivors to develop lung SMN [adjusted HR (aHR) = 1.47; 95% confidence interval (95% CI), 1.13–1.91] but were not more likely to die from lung SMN (aHR = 0.84; 95% CI, 0.56–1.27). Primary cancer treatment with both chemotherapy and radiation was associated with a greater likelihood of lung SMN (aHR = 1.41; 95% CI, 1.11–1.80) compared with receiving neither. Conclusions: Lung SMN has a long latency and high mortality among survivors of AYA cancer. Impact: More research is needed on lung cancer prevention, education, and early detection, particularly among survivors at higher risk.
Year:
2025
Supplemental Figure 2 shows overall 5-year survival curves by subsequent malignant neoplasm (SMN) type from SMN diagnosis among those with primary adolescent and young adult (AYA) (a) female breast cancer, (b) cervical/uterine cancer, (c) Hodgkin lymphoma who were diagnosed between 1998 and 2020 (California Cancer Registry Data). Shaded areas represent 95% confidence intervals.
Year:
2025
Supplemental Figure 1 shows the cumulative incidence over time of developing subsequent malignant neoplasm (SMN) among survivors of primary adolescent and young adult (AYA) (a) female breast cancer who developed lung (n = 112) and non-lung (n = 4,971) SMN, (b) cervical/uterine cancer who developed lung (n = 95) and non-lung (n = 1,451) SMN, (c) Hodgkin lymphoma who developed lung (n = 70) and non-lung (n = 1,129) and who were diagnosed with a primary cancer between 1998 and 2020 (California Cancer Registry Data).
Year:
2025
Background Women harboring mutations in breast cancer susceptibility genes are at increased lifetime risk of developing breast cancer and are faced with decisions about risk management, including whether to undergo high‐risk screening or risk‐reducing mastectomy (RRM). National guidelines recommend BRCA1 or BRCA2 mutation carriers consider RRM, but that carriers of moderate penetrance mutations (e.g., ATM or CHEK2 ) should be managed based on family history. We aimed to investigate determinants of decision for RRM, and hypothesized that mutation status, age, family history, partner status, and breast cancer would impact RRM decision making. Methods We performed a retrospective study assessing RRM decisions for 279 women. Results Women with BRCA and moderate penetrance gene mutations, a personal history of breast cancer, or a first degree relative with a history of breast cancer were more likely to undergo RRM. Breast cancer status and age showed an interaction effect such that women with breast cancer were less likely to undergo RRM with increasing age. Conclusion Although national guidelines do not recommend RRM for moderate penetrance carriers, the rates of RRM for this population approached those for BRCA mutation carriers. Further insights are needed to better support RRM decision‐making in this population.
Year:
2022
Collaborators (5)
Jorge Nieva
Professor of Clinical Medicine
University of Southern California
Yueh-Yun Chi
Research Professor
University of Southern California
Christopher McNair
Thomas Jefferson University
David R. Freyer
-
Michael Roth
Associate Professor of Pediatrics
The University of Texas MD Anderson Cancer Center Children's Cancer Hospital
Make your next move.
Prepare your application
Review drafts before you send them.